Longbio Pharma
Clinical trials sponsored by Longbio Pharma, explained in plain language.
-
New injection shows promise for kidney disease patients
Disease control Not yet recruitingThis study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. The drug is given as an add-on to standard care. The goal is to see if it can reduce protein in the urine, improve…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 26, 2026 10:51 UTC
-
New hope for PNH patients: LP-005 Long-Term safety trial begins
Disease control Not yet recruitingThis study is for people with PNH who already finished a previous LP-005 trial. It will check if the drug is safe and works well over a longer time. About 30 adults will take part. The goal is to control the disease and reduce symptoms like fatigue and blood clots.
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
New injection could shrink nasal polyps and ease breathing
Disease control Not yet recruitingThis study tests an experimental drug called LP-003 for people with chronic sinusitis and nasal polyps (growths in the nose). The goal is to see if it can shrink polyps and reduce stuffiness. About 150 adults will receive either the drug or a placebo, and their progress will be t…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 18, 2026 12:10 UTC